Bausch Health (BHC) closed the last trading session at $7.57, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.50 indicates a 25.5% upside potential.The average comprises six short-term price targets ranging from a low of $6 to a high of $12, with a standard deviation of $2.59. While the lowest estimate indicates a decline of 20.7% from the current price level, the m ...

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced today that it has entered into an option agreement granting leading global eye health company Bausch + Lomb the right to acquire the company. This strategic move aligns with a shared goal of advancing groundbreaking treatments addressing unmet medical needs in ophthalmology. InflammX’s pipelin ...

Bausch Health Companies (NYSE: BHC , TSX: BHC:CA ) is one of the undervalued stocks currently, trading only at trailing EV/EBITDA of 8.03x. The expected complete spin-off of its Bausch + Lomb ( BLCO ) will have more benefitHi there! I am an equity research analyst by profession but a trader by heart, with a background in accounting. I try my best to be a responsible investor, guided by my expertise in fundamental and technical analysis. I enjoy surfing and riding the trends about equity, currencies and cryp ...

A month has gone by since the last earnings report for Bausch Health (BHC) . Shares have lost about 11.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Bausch due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Bausch Health Q3 Earnings and Revenues Top, Xifaxan Boo ...

Investors might want to bet on Bausch Health (BHC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing ea ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Bausch Health (BHC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bausch Health is a member of the Medical sector. This group includes 1024 individual stocks and c ...

Shares of Bausch Health Companies Inc. (BHC) gained 12.6% after the company reported better-than-expected third-quarter results on Oct. 30. The company also raised its annual revenue guidance.Adjusted earnings per share of $1.12 beat the Zacks Consensus Estimate of $1.03. The reported figure increased from $1.03 in the year-ago quarter due to higher revenues.Total revenues of $2.5 billion were up 12% year over year. The top line also beat the Zacks Consensus Estimate of $2.4 billion.Excluding the impact of ...

Core Viewpoint - Bausch Health reported strong financial results for the quarter ended September 2024, with revenue and EPS exceeding expectations, indicating positive growth trends in various segments [1][3]. Financial Performance - Total revenue for Bausch Health reached $2.51 billion, marking a 12.2% increase year-over-year and surpassing the Zacks Consensus Estimate of $2.43 billion by 3.33% [1]. - Earnings per share (EPS) were reported at $1.12, an increase from $1.03 in the same quarter last year, representing an EPS surprise of 8.74% [1]. Segment Performance - Bausch + Lomb revenues totaled $1.20 billion, slightly below the average estimate of $1.21 billion, but still reflecting an 18.8% year-over-year increase [3]. - Revenues excluding Bausch + Lomb were $1.31 billion, exceeding the average estimate of $1.22 billion, with a year-over-year growth of 6.7% [3]. - Diversified Products generated $269 million, surpassing the average estimate of $248.43 million, with a year-over-year change of 3.9% [3]. - Solta Medical revenues reached $112 million, exceeding the estimate of $99.70 million, showing a significant year-over-year increase of 34.9% [3]. - International revenues were $291 million, above the average estimate of $280.64 million, reflecting a 5.8% year-over-year growth [3]. - Salix revenues amounted to $642 million, exceeding the average estimate of $590.26 million, with a year-over-year increase of 4.6% [3]. - Product sales totaled $2.48 billion, surpassing the average estimate of $2.40 billion, indicating a 12.2% year-over-year change [3]. - Other revenues were reported at $28 million, exceeding the estimate of $23.07 million, with a year-over-year increase of 12% [3]. - Bausch + Lomb Vision Care revenues were $684 million, slightly below the estimate of $686.92 million, with a year-over-year change of 5.6% [3]. - Bausch + Lomb Surgical revenues were $206 million, compared to the average estimate of $213.09 million, reflecting an 11.4% year-over-year increase [3]. - Bausch + Lomb Ophthalmic Pharmaceuticals revenues reached $306 million, slightly below the estimate of $312.07 million, but showing a substantial year-over-year increase of 75.9% [3]. Stock Performance - Bausch shares have returned -1.3% over the past month, contrasting with the Zacks S&P 500 composite's +1.8% change, indicating underperformance relative to the broader market [4].

Company Performance - Bausch Health reported quarterly earnings of $1.12 per share, exceeding the Zacks Consensus Estimate of $1.03 per share, and showing an increase from $1.03 per share a year ago, representing an earnings surprise of 8.74% [1] - The company posted revenues of $2.51 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.33%, compared to revenues of $2.24 billion in the same quarter last year [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Future Outlook - The current consensus EPS estimate for the coming quarter is $1.12 on revenues of $2.52 billion, and for the current fiscal year, it is $3.60 on revenues of $9.51 billion [7] - The estimate revisions trend for Bausch is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [3] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

| --- | --- | --- | --- | --- | --- | --- | |------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | 3Q 2024 | | | | | | | | EARNINGS | | | | | | | | OCTOBER 30, 2024 | | | | | | | | | | | | | | | 1 Forward-Looking Statements; Non-GAAP Information Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limite ...